These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
987 related articles for article (PubMed ID: 26742937)
1. Ki-67 is a prognostic marker for hormone receptor positive tumors. Pérez-López ME; García-Gómez J; Alves MT; Paradela A; García-Mata J; García-Caballero T Clin Transl Oncol; 2016 Oct; 18(10):996-1002. PubMed ID: 26742937 [TBL] [Abstract][Full Text] [Related]
2. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index. Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822 [TBL] [Abstract][Full Text] [Related]
3. Ki67 expression in breast cancer. Correlation with prognostic markers and clinicopathological parameters in Saudi patients. Elkablawy MA; Albasri AM; Mohammed RA; Hussainy AS; Nouh MM; Alhujaily AS Saudi Med J; 2016 Feb; 37(2):137-41. PubMed ID: 26837394 [TBL] [Abstract][Full Text] [Related]
4. Ki67 Frequency in Breast Cancers without Axillary Lymph Node Involvement and its Relation with Disease-free Survival. Shandiz FH; Shabahang H; Afzaljavan F; Sharifi N; Tavasoli A; Afzalaghaee M; Roshanzamir E; Pasdar A Asian Pac J Cancer Prev; 2016; 17(3):1347-50. PubMed ID: 27039770 [TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic and prognostic evaluation of invasive breast carcinoma molecular subtypes and GATA3 expression. Demir H; Turna H; Can G; Ilvan S J BUON; 2010; 15(4):774-82. PubMed ID: 21229645 [TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of the progesterone receptor status in Ki67-high and -low Luminal B-like HER2-negative breast cancers. Sato K; Miyashita M; Ishida T; Suzuki A; Tada H; Watanabe G; Sato-Tadano A; Watanabe M; Ohuchi N Breast Cancer; 2016 Mar; 23(2):310-7. PubMed ID: 25380989 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab. Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689 [TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of geminin expression levels in Ki67-high subset of estrogen receptor-positive and HER2-negative breast cancers. Yagi T; Inoue N; Yanai A; Murase K; Imamura M; Miyagawa Y; Enomoto Y; Nishimukai A; Takatsuka Y; Hirota S; Akazawa K; Miyoshi Y Breast Cancer; 2016 Mar; 23(2):224-30. PubMed ID: 25082658 [TBL] [Abstract][Full Text] [Related]
9. Correlation between hormone receptor status and age, and its prognostic implications in breast cancer patients in Bahrain. AlZaman AS; Mughal SA; AlZaman YS; AlZaman ES Saudi Med J; 2016 Jan; 37(1):37-42. PubMed ID: 26739972 [TBL] [Abstract][Full Text] [Related]
10. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013. Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M; Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648 [TBL] [Abstract][Full Text] [Related]
11. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis. Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532 [TBL] [Abstract][Full Text] [Related]
12. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer. Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572 [TBL] [Abstract][Full Text] [Related]
13. Impact of molecular subtypes classification concordance between preoperative core needle biopsy and surgical specimen on early breast cancer management: Single-institution experience and review of published literature. Meattini I; Bicchierai G; Saieva C; De Benedetto D; Desideri I; Becherini C; Abdulcadir D; Vanzi E; Boeri C; Gabbrielli S; Lucci F; Sanchez L; Casella D; Bernini M; Orzalesi L; Vezzosi V; Greto D; Mangoni M; Bianchi S; Livi L; Nori J Eur J Surg Oncol; 2017 Apr; 43(4):642-648. PubMed ID: 27889196 [TBL] [Abstract][Full Text] [Related]
14. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up. Buta M; Džodić R; Đurišić I; Marković I; Vujasinović T; Markićević M; Nikolić-Vukosavljević D Tumour Biol; 2015 Sep; 36(10):8193-200. PubMed ID: 25994573 [TBL] [Abstract][Full Text] [Related]
15. Associations between the standardized uptake value of (18)F-FDG PET/CT and the prognostic factors of invasive lobular carcinoma: in comparison with invasive ductal carcinoma. Jung NY; Kim SH; Choi BB; Kim SH; Sung MS World J Surg Oncol; 2015 Mar; 13():113. PubMed ID: 25889560 [TBL] [Abstract][Full Text] [Related]
16. Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both? Raica M; Cîmpean AM; Ceausu RA; Fulga V; Nica C; Rudico L; Saptefrati L Anticancer Res; 2014 Mar; 34(3):1435-40. PubMed ID: 24596391 [TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of Ki-67 in chemotherapy-naive breast cancer patients with 10-year follow-up. Nishimiya H; Kosaka Y; Yamashita K; Minatani N; Kikuchi M; Ema A; Nakamura K; Waraya M; Sengoku N; Tanino H; Kuranami M; Watanabe M Anticancer Res; 2014 Jan; 34(1):259-68. PubMed ID: 24403472 [TBL] [Abstract][Full Text] [Related]
18. Invasive breast cancer: a significant correlation between histological types and molecular subgroups. Caldarella A; Buzzoni C; Crocetti E; Bianchi S; Vezzosi V; Apicella P; Biancalani M; Giannini A; Urso C; Zolfanelli F; Paci E J Cancer Res Clin Oncol; 2013 Apr; 139(4):617-23. PubMed ID: 23269487 [TBL] [Abstract][Full Text] [Related]
19. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer. Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126 [TBL] [Abstract][Full Text] [Related]
20. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer. Criscitiello C; Disalvatore D; De Laurentiis M; Gelao L; Fumagalli L; Locatelli M; Bagnardi V; Rotmensz N; Esposito A; Minchella I; De Placido S; Santangelo M; Viale G; Goldhirsch A; Curigliano G Breast; 2014 Feb; 23(1):69-75. PubMed ID: 24314620 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]